Back
Tenet Healthcare 10K Form
Buy
62
THC
Tenet Healthcare
Last Price:
163.85
Seasonality Move:
10.43%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-04-30 | 10Q | THC/Tenet Healthcare Quarterly |
2024-02-16 | 10K | THC/Tenet Healthcare Annual |
2023-10-30 | 10Q | THC/Tenet Healthcare Quarterly |
2023-07-31 | 10Q | THC/Tenet Healthcare Quarterly |
2023-04-28 | 10Q | THC/Tenet Healthcare Quarterly |
2023-02-21 | 10K | THC/Tenet Healthcare Annual |
Receive THC News And Ratings
See the #1 stock for the next 7 days that we like better than THC
THC Financial Statistics
Sales & Book Value
Annual Sales: | $20.55B |
---|---|
Cash Flow: | $829M |
Price / Cash Flow: | 6.78 |
Annual Sales: | $40.32 |
Price / Book: | 4.03 |
Profitability
EPS (TTM): | 31.21000 |
---|---|
Net Income (TTM): | $3.13B |
Gross Margin: | $16.96B |
Return on Equity: | 45.56% |
Return on Assets: | 10.9% |
Tenet Healthcare Earnings Forecast
Key Tenet Healthcare Financial Ratios
- The Gross Profit Margin over the past 38 years for THC is 82.53%.
- The Selling, General & Administrative Expenses for THC have been equal to 44.51% of Gross Profit Margin.
- The Research & Development expenses have been 0.00% of Revenue.
- The Interest Expense is 147.46% of Operating Income.
- The Net Earning history of THC is 2.97% of Total Revenues.
- Per Share Earnings over the last 40 years have been positive in 21 years.
Tenet Healthcare Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | S&P500 |
---|---|
Industry: | Health Care Providers & Services |
Sector: | Health Care |
Current Symbol: | THC |
CUSIP: | 88033G |
Website: | tenethealth.com |
Debt
Debt-to-Equity Ratio: | 3.36 |
---|---|
Current Ratio: | 1.58 |
Quick Ratio: | 1.39 |
Price-to-Earnings
Trailing P/E Ratio: | 28.44 |
---|---|
Forward P/E Ratio: | 14.18 |
THC Technical Analysis vs Fundamental Analysis
Buy
62
Tenet Healthcare (THC)
is a Buy
Is Tenet Healthcare a Buy or a Sell?
-
Tenet Healthcare stock is rated a Buy
The current Tenet Healthcare [THC] share price is $162.38. The Score for THC is 62, which is 24% above its historic median score of 50, and infers lower risk than normal.